Proceeds from the financing round will be used to advance Metagenomi's in vivo and ex vivo gene editing therapeutic programs from preclinical development and into the clinic. Additionally, funding will support the expansion of Metagenomi's manufacturing, automation, and artificial intelligence infrastructure and its differentiated toolbox of next-generation gene editing systems.

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA.

The series B financing round was led by PFM Health Sciences and Farallon Capital Management. New investors include Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital, Marshall Wace, Novo Holdings, and Bristol Myers Squibb. The financing round also included investment from strategic partner Moderna as well as existing investors RA Capital Management, Leaps by Bayer, and Humboldt Fund, among others.

Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies...